Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Marine lipids, particularly omega-3 fatty acids such as EPA and DHA, have been researched for their anti-inflammatory properties, which are relevant to autoimmune diseases like Hashimoto's Disease (autoimmune thyroiditis). The rationale for their use is based on the concept that chronic inflammation underlies much of the tissue damage in Hashimoto's, and dietary interventions that reduce inflammation may offer benefit. Some studies have shown that omega-3 supplementation can lower markers of inflammation (e.g., C-reactive protein, interleukin-6) and modulate immune function. However, direct evidence specifically examining marine lipid supplementation in Hashimoto’s patients is limited and largely extrapolated from broader research on autoimmune and inflammatory diseases.

A few small-scale studies and case reports suggest that omega-3s might improve subjective symptoms such as fatigue and joint pain in Hashimoto’s, but they have not been shown conclusively to alter thyroid antibody levels, hormone function, or disease progression. Major clinical guidelines do not currently recommend marine lipids specifically for Hashimoto’s management, though they may be advised as part of a heart-healthy diet. Therefore, while there is some scientific rationale and indirect evidence, the clinical evidence for the benefit of marine lipids in Hashimoto's Disease is weak (rated 2/5), and supplementation should not substitute for established medical therapies.

More about Marine lipid
More about Hashimoto's Disease

Other ingredients used for Hashimoto's Disease

Other health conditions supported by Marine lipid

Products containing Marine lipid